Navigation


Login

← Back to Dashboard | Research

U.S. IPO & Equity Capital Markets Brief
Partial Access

U.S. IPO & Equity Capital Markets Brief

Nov 16, 2026 Eric Friedman

Anthropic's IPO is set to challenge investor appetite with a massive offering. Explore the implications of this landmark event in the equity market.

Period: November 16–20, 2026

Coverage: Traditional operating-company IPOs on U.S. exchanges and consequential U.S. equity offerings of at least $100 million. Calendar checked November 16.

Anthropic is the week’s only qualifying scheduled IPO

ANT is a test of whether investors can absorb a $61 billion public offering and still bid for stock after allocations. The book reportedly has depth. The opening is less straightforward: the public offer is large in dollars but small relative to fully diluted ownership, and hundreds of millions of existing shares may become eligible for sale on day one.

Issuer Pricing / debut (ET) Filed range / base shares Base gross Exchange / leads
Anthropic (ANT) Nov. 18 / Nov. 19 expected $70–$78 / 825.0M $57.75–$64.35B; $61.05B midpoint Nasdaq Global Select; Goldman Sachs, Morgan Stanley

What is actually being sold

The November 10 S-1/A supersedes the earlier reported raise estimates. At $74, 801.35 million primary shares produce $59.30 billion gross for Anthropic, and 23.65 million secondary shares produce $1.75 billion gross for selling holders. The 123.75 million-share primary greenshoe would take public gross to $70.21 billion at midpoint if fully exercised. November 18 is the expected pricing date, not the first trade; November 19 is the expected U.S. debut, subject to completion.

The separate $26 billion Class N placement would bring combined base gross to $87.05 billion at midpoint, but should not be counted in the opening float. Seven strategic counterparties are participating, including NVIDIA, Microsoft and Google; part of Google’s allocation funds a prior obligation. Goldman Sachs and Morgan Stanley lead a broad syndicate that includes J.P. Morgan, Citi, Barclays and Wells Fargo.

Strong book, but watch who is left to buy

IPO Prophet® displays a 9.15/10 pre-offering rating and a Heat Index of 42, Warm. Bloomberg reported November 12 that the book was about six times covered and that existing backers may receive priority. This is reported order interest, not price-tested coverage or confirmed allocations. If existing backers take sizable allocations and other institutions are cut back, the resulting buy imbalance could support the opening. If large orders are price-sensitive or already fully allocated, the headline multiple may overstate follow-through.

Day-one supply can be larger than the headline float

The 825 million base shares are the starting point. The prospectus allows up to 316 million additional Class A shares held by eligible non-founder insiders, employees and consultants to become eligible for sale on the first trading day. That could lift the base-plus-eligible pool to 1.141 billion shares before any shoe effect, roughly 38% larger than the base deal. Eligibility is not an order to sell. Monitor actual sell-side interest rather than assuming those shares are unavailable or will all trade.

The prospectus also identifies up to 299 million shares potentially eligible on day 27, with further releases later. The opening auction can therefore be tight even with meaningful supply behind it. Keep the shoe, lockup releases and private placement separate; they do not create equivalent day-one selling pressure.

What a higher opening price would imply

Using the roughly 13.1 billion-share prospectus net-tangible-book-value denominator as a capitalization reference, the filed range implies about $0.92–$1.02 trillion of equity value. The widely reported roughly $1.3–$1.4 trillion headline uses a more diluted basis. Do not compare valuation figures without aligning share counts.

Illustrative print vs. $74 midpoint Equity at 13.1B reference shares Read-through
$74 0.0% $0.97T Offer midpoint; not a forecast
$78 +5.4% $1.02T Top of filed range
$90 +21.6% $1.18T Above-range buyers must absorb added supply
$100 +35.1% $1.31T Do not infer durable demand from the opening premium alone

The valuation test is whether growth converts to cash. Q3 revenue was $17.0 billion and operating loss was $567 million. The prospectus disclosed about $895.4 billion of compute and infrastructure commitments as of and after September 30, not an amount due at once. Capacity delivery, partner financing, competition and founder voting control matter independently of the opening imbalance.

ECM backdrop and watchlist

No other qualifying IPO or separate $100 million-plus follow-on with confirmed pri

Stay Updated with IPO Insights

Get the latest IPO news, analysis, and trading opportunities delivered to your inbox.

Subscribe to Newsletter